Technical Analysis for ABOS - Acumen Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Fell Below 50 DMA | Bearish | -5.61% | |
| 180 Bearish Setup | Bearish Swing Setup | -5.61% | |
| BB Squeeze Ended | Range Expansion | -5.61% | |
| Crossed Above 50 DMA | Bullish | -9.25% | |
| Bollinger Band Squeeze | Range Contraction | -9.25% | |
| BB Squeeze Started | Range Contraction | -9.25% | |
| Fell Below 50 DMA | Bearish | -4.85% | |
| BB Squeeze Ended | Range Expansion | -4.85% |
| Alert | Time |
|---|---|
| Down 5% | about 9 hours ago |
| 60 Minute Opening Range Breakdown | about 13 hours ago |
| Fell Below Lower Bollinger Band | about 13 hours ago |
| Lower Bollinger Band Support | about 15 hours ago |
| Down 3% | about 15 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/06/2024
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Immunotherapy Alzheimer's Disease Neurodegenerative Diseases Amyloid Amyloidosis Neurodegeneration Regulus Therapeutics Targeted Immunotherapy Treatment Of Alzheimer's Amyloid Beta
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Immunotherapy Alzheimer's Disease Neurodegenerative Diseases Amyloid Amyloidosis Neurodegeneration Regulus Therapeutics Targeted Immunotherapy Treatment Of Alzheimer's Amyloid Beta
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.3099 |
| 52 Week Low | 1.8101 |
| Average Volume | 349,127 |
| 200-Day Moving Average | 4.29 |
| 50-Day Moving Average | 3.82 |
| 20-Day Moving Average | 3.95 |
| 10-Day Moving Average | 3.80 |
| Average True Range | 0.25 |
| RSI (14) | 39.76 |
| ADX | 28.27 |
| +DI | 15.85 |
| -DI | 30.50 |
| Chandelier Exit (Long, 3 ATRs) | 3.67 |
| Chandelier Exit (Short, 3 ATRs) | 4.07 |
| Upper Bollinger Bands | 4.35 |
| Lower Bollinger Band | 3.54 |
| Percent B (%b) | -0.01 |
| BandWidth | 20.56 |
| MACD Line | -0.07 |
| MACD Signal Line | -0.02 |
| MACD Histogram | -0.053 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.89 | ||||
| Resistance 3 (R3) | 3.93 | 3.85 | 3.83 | ||
| Resistance 2 (R2) | 3.85 | 3.76 | 3.83 | 3.81 | |
| Resistance 1 (R1) | 3.69 | 3.70 | 3.65 | 3.65 | 3.79 |
| Pivot Point | 3.61 | 3.61 | 3.59 | 3.59 | 3.61 |
| Support 1 (S1) | 3.45 | 3.52 | 3.41 | 3.41 | 3.27 |
| Support 2 (S2) | 3.37 | 3.46 | 3.35 | 3.25 | |
| Support 3 (S3) | 3.21 | 3.37 | 3.23 | ||
| Support 4 (S4) | 3.17 |
